Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417223 | 1.00 | MAPT (0.45) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL747872 | 1.00 | MAPT (0.45) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| Hydrogen Sulfide SCHEMBL27945862 | 0.98 | MAPT (0.44) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| Hydrogen Sulfide SCHEMBL28147035 | 0.98 | MAPT (0.44) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL28419180 | 0.96 | MAPT (0.42) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| Acetic Acid SCHEMBL21359017 | 0.94 | MAPT (0.50) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL16703745 | 0.84 | FOLH1 (0.34) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL16703747 | 0.84 | FOLH1 (0.34) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL2192913 | 0.81 | KDM4E (0.47) | MAPTSMN1; SMN2KDM4ETHRBALOX15 | |
| SCHEMBL2286681 | 0.81 | TGFBR1 (0.42) | MAPTSMN1; SMN2TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120041413-A | Enzyme composition and application thereof in preparation of allyl cysteine | 深圳瑞德林生物技术有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-115245589-B | Novel degradable embolism microsphere with controllable particle size and preparation method thereof | 苏州浩微生物医疗科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118178374-A | Implant carrying S-propargyl cysteine and preparation method thereof | 依诺医药(广东)有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116270952-A | Extract for relieving gout and extraction method and application thereof | 佳木斯大学 | 2023-06-23 | — | — | CN | claimed |
| CN-114956704-B | Composite curing agent for improving early compressive strength of heavy metal polluted bottom mud | 中交天津港湾工程研究院有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-112972380-B | Preparation method and application of multifunctional novel drug delivery system preparation | 潍坊中医药产业技术研究院 | 2022-11-22 | — | — | CN | claimed |
| CN-113081965-B | Sensitivity and H based on ROS 2 S-responsive multifunctional liposome and preparation method and application thereof | 烟台大学 | 2022-11-11 | — | — | CN | claimed |
| CN-115245590-A | Novel degradable embolism microsphere and preparation method thereof | 苏州浩微生物医疗科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115245589-A | Novel degradable embolism microsphere with controllable particle size and preparation method thereof | 苏州浩微生物医疗科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-114956704-A | Composite curing agent for improving early compressive strength of heavy metal polluted bottom mud | 中交天津港湾工程研究院有限公司 | 2022-08-30 | — | — | CN | claimed |
| EP-2165612-A1 | Flavour composition | Givaudan SA (CH) | 2010-03-24 | — | — | EP | claimed |
| CN-101467991-A | Uses of allyl cysteine and analogue thereof in preparing medicament for treating myocardial damage | UNIV FUDAN (CN) | 2009-07-01 | — | — | CN | claimed |
| EP-1880020-A4 | CELLULAR BIOMARKER ANTIOXIDANT ASSAY AND USES THEREOF | UNIV TENNESSEE RES FOUNDATION (US) | 2009-05-20 | — | — | EP | claimed |
| US-20080312128-A1 | Cellular Biomarker Antioxidant Assay and Uses Thereof | CHAUM EDWARD | 2008-12-18 | — | — | US | claimed |
| WO-2008023339-A2 | METHOD AND COMPOSITION FOR THE DEPOSITION OF PALLADIUM LAYERS AND PALLADIUM ALLOY LAYERS | ENTHONE INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-1880020-A2 | CELLULAR BIOMARKER ANTIOXIDANT ASSAY AND USES THEREOF | University of Tennessee Research Foundation (US) | 2008-01-23 | — | — | EP | claimed |
| US-20070031510-A1 | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto | FLAVIN-KOENIG DANA | 2007-02-08 | — | — | US | claimed |
| WO-2006118988-A2 | CELLULAR BIOMARKER ANTIOXIDANT ASSAY AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050025735-A1 | Method for time-dependent decrease of pH in a cosmetic composition and a composition for permanent hair shaping having time-dependent decreasing wave-shaping efficiency | WELLA AKTIENGESELLSCHAFT (DE) | 2005-02-03 | — | — | US | claimed |
| EP-1297826-A1 | Nasal pharmaceutical compositions containing a NK-2 antagonist | Menarini Ricerche S.p.A. (IT) | 2003-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025735-A1 | Method for time-dependent decrease of pH in a cosmetic composition and a composition for permanent hair shaping having time-dependent decreasing wave-shaping efficiency | CUTA, APEH, HAAO | MAPT 4591/4885SMN1; SMN2 4605/4885KDM4E 1713/4885 |
| US-20070031510-A1 | Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto | GOT1, MGST1, SHARPIN | MAPT 529/4885SMN1; SMN2 2883/4885KDM4E 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.